research use only

Beta-Lapachone Topoisomerase inhibitor

Name: Beta-Lapachone
Brand: Selleck Chemicals
SKU: S7261
Availability: InStock
Rating: 5 (11 reviews)

Cat.No.S7261

Beta-Lapachone (β-Lapachone, ARQ-501) is a selective DNA topoisomerase I inhibitor, exhibiting no inhibitory activities against DNA topoisomerase II or ligase. Phase 2.

Chemical Structure

Molecular Weight: 242.27

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	DNA/RNA Synthesis HDAC PPAR PARP Sirtuin ATM/ATR Casein Kinase eIF MDM DNA-PK DHFR Nucleoside Analog/Antimetabolite DNA alkylator Telomerase Thymidylate Synthase CRISPR/Cas9 RAD51 BMI-1 LIM kinase RNR Alkylating Agent NUDIX G-quadruplex High-mobility Group OGG1 MTH1 SMN FENs WRN Pax
Related Products	Camptothecin (CPT) (S)-10-Hydroxycamptothecin Amonafide Voreloxin (SNS-595) hydrochloride Ellagic acid Genz-644282 Hydroxy Camptothecine Rubitecan Eleutherin Clinafloxacin ABBV-969 Payload SW-044248 Cu(II)-Elesclomol Pefloxacin Mesylate Dihydrate Amsacrine hydrochloride Gepotidacin Topoisomerase IIα Antibody [H22C21] Cholesteryl hemisuccinate Dxd Trovafloxacin Ellipticine Betulinic acid Exatecan 7-Ethylcamptothecin 9-amino-CPT (9-Aminocamptothecin) Amsacrine Topoisomerase I Antibody [C12J2] Belotecan (CKD-602) hydrochloride Topoisomerase IIα Antibody [E2A15] Flumequine

Chemical Information, Storage & Stability

Molecular Weight	242.27	Formula	C₁₅H₁₄O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	4707-32-8	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	β-Lapachone, ARQ-501			Smiles	CC1(CCC2=C(O1)C3=CC=CC=C3C(=O)C2=O)C

Solubility

In vitro
Batch:

DMSO : 33 mg/mL (136.21 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 16 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.000mg/ml (8.26mM)	Taking the 1 mL working solution as an example, add 50 μL of 40 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.000mg/ml (8.26mM)	Taking the 1 mL working solution as an example, add 50 μL of 40 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Topo I ^[1] IDO1 ^[4] 0.44 μM
In vitro	Beta-Lapachone inhibits DNA relaxation induced by DNA topoisomerase I in a dose-dependent manner. ^[1] Treatment of this compound (100 nM or greater) results in >95% inhibition of Topo I DNA unwinding activity compared to the DMSO control. This chemical (1-5 μM) causes a block in G0/G1 of the cell cycle and induces apoptosis by locking Topo I onto DNA and blocking replication fork movement in HL-60 and three human prostate cancer (DU-145, PC-3, and LNCaP) cells. ^[2] It facilitates the migration of mouse 3T3 fibroblasts and human endothelial EAhy926 cells through different MAPK signaling pathways, and thus accelerates scrape-wound healing in vitro. ^[3] In addition, this compound inhibits purified recombinant IDO1 activity through uncompetitive inhibition with IC50 of 0.44 μM, and it also exhibits superior retention of intracellular IDO1 inhibitory activity with an IC50 of 1.0 μM, partially dependent on biotransformation by NQO1. ^[4] This chemical induces programmed necrosis of NQO1+ cancer cells by NQO1-dependent reactive oxygen species (ROS) formation and PARP1 hyperactivation. [5]
Kinase Assay	Topoisomerase I Catalytic Actioity Assay ^[1]
Kinase Assay	Topoisomerase I Catalytic Activity Assay: The enzymatic activity is analyzed by the DNA unwinding assay. DNA topoisomerase I, from TopoGEN (1 unit, which is defined as the amount of enzyme that converts 0.5 μg of superhelical DNA to the relaxed state in 30 minutes at 37 °C), is incubated with 0.5 μg of 6x174 RF DNA, in the presence or absence of Beta-Lapachone, in 20 μL of relaxation buffer (50 mM Tris (pH 7.5), 50 mM KCI, 10 mM MgCl₂, 0.5 mM dithiothreitol, 0.5 mM EDTA, 30 μg/mL bovine serum albumin) for 30 minutes at 37 °C. Reactions are stopped by adding 1% SDS and proteinase K (50 μg/mL). After an additional 1-hour incubation at 37 °C, the products are separated by electrophoresis in 1% agarose gel in TAE buffer (0.04 M tris acetate, 0.001 M EDTA). The gel is stained with ethidium bromide after electrophoresis. The photographic negative is scanned with an NIH image analysis system.
In vivo	Beta-lapachone treatment (50 mg/kg) leads to potent inhibition of in vivo tumor growth in a xenograft mouse model of human ovarian cancer, and the combination of this compound and taxol produces a synergistic induction of apoptosis. ^[6] In normal and diabetic (db/db) mice, treatment of this chemical results in a faster healing process than vehicle only. ^[3]
References	[1] https://pubmed.ncbi.nlm.nih.gov/8226754/ [2] https://pubmed.ncbi.nlm.nih.gov/7641180/ [3] https://pubmed.ncbi.nlm.nih.gov/18650264/ [4] https://pubmed.ncbi.nlm.nih.gov/24023520/ [5] https://pubmed.ncbi.nlm.nih.gov/22532167/ [6] https://pubmed.ncbi.nlm.nih.gov/10557327/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00524524	Completed	Advanced Solid Tumors	ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA)	August 2007	Phase 1
NCT00622063	Completed	Cancer	ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA)	December 2006	Phase 1\|Phase 2
NCT00358930	Completed	Head and Neck Neoplasms\|Carcinoma Squamous Cell	ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA)	July 2006	Phase 2
NCT00102700	Completed	Pancreatic Cancer\|Adenocarcinoma	ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA)	January 2005	Phase 2
NCT00099190	Completed	Carcinoma	ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA)	December 2004	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):